Elevated Hsp90-beta contributes to differential diagnosis of pleural effusion caused by lung cancer and correlates with malignant biological behavior of lung cancer

Table 3 Correlation between the level of Hsp90-beta in MPE and serum in lung cancer patients with MPE and clinicopathologic factors

Groups	Items	N	Level of Hsp90-beta in MPE				Level of Hsp90-beta in serum
Groups	Items	N	M ± SD(ng/mL)	DF	Statistical value	P	M ± SD(ng/mL)	DF	Statistical value	P
Sex	Male	60	1.98 ± 0.36	105	T = −0.78	0.63	1.39 ± 0.16	105	T = −0.82	0.09
Sex	Female	47	2.13 ± 0.49	105	T = −0.78	0.63	1.42 ± 0.09	105	T = −0.82	0.09
Age	< 60	38	1.92 ± 0.16	105	T = −1.48	0.14	1.38 ± 0.18	105	T = −1.49	0.12
Age	≥60	69	2.01 ± 0.19	105	T = −1.48	0.14	1.42 ± 0.13	105	T = −1.49	0.12
Smoking	Yes	35	1.99 ± 0.26	105	T = −0.878	0.38	1.40 ± 0.19	105	T = −0.878	0.382
Smoking	No	72	2.06 ± 0.31	105	T = −0.878	0.38	1.41 ± 0.17	105	T = −0.878	0.382
Histology	LAC	61	2.00 ± 0.19	2	F = 1.503	0.227	1.41 ± 0.19	2	F = 1.602	0.231
	LSCC	37	1.98 ± 0.11				1.39 ± 0.14
	SCLC	9	2.03 ± 019				1.44 ± 0.22
Pathologic grade	Undifferentiated	9	2.03 ± 0.10^a	3	F = 9.370	< 0.001	1.44 ± 0.12^a	3	F = 9.370	< 0.001
	Poorly	73	2.12 ± 0.07^a				1.43 ± 0.17^a
	Moderate	15	1.82 ± 0.13				1.33 ± 0.16
	Well	10	1.80 ± 0.09				1.36 ± 0.13
T stage	T2	15	1.81 ± 0.11	2	F = 9.996	0.009	1.35 ± 0.10	2	F = 3.778	0.013
	T3	20	1.80 ± 0.13				1.37 ± 0.13
	T4	63	2.18 ± 0.19^b				1.46 ± 0.15^b
	Unavailable	9	1.82 ± 0.09				1.44 ± 0.10^c
Lymphatic invasion	N1	10	1.82 ± 0.23	2	F = 10.591	< 0.001	1.33 ± 0.08	2	F = 11.302	< 0.001
	N2	24	1.85 ± 0.14				1.36 ± 0.21
	N3	63	2.09 ± 0.22^c				1.46 ± 0.17^c
	Unavailable	10	1.94 ± 0.09				1.43 ± 0.19

MPE malignant pleural effusion, LAC lung adenocarcinoma, LSCC lung squamous cell carcinoma, SCLC small cell lung cancer; ^a: undifferentiated and poorly compared with moderate and well; ^b: T4 compared with T3 and T2; ^c: N3 compared with N2 and N1; M ± SD mean ± standard deviation, DF degree of freedom

ISSN: 1471-2466